Mr Helfgott joined Novo Nordisk in April 2019 as executive vice
president and head of Biopharm.
Mr Helfgott joined Novo Nordisk from AstraZeneca, UK, where he was
global vice president in charge of the company's Cardiovascular,
Metabolism and Renal global franchise, supervising both assets in
development and on the market. He joined AstraZeneca in 2005 in an
international sales effectiveness role and has since held operational
leadership roles with increasing responsibilities in Italy, Spain and
at corporate headquarters. Prior to this, Mr Helfgott was with
McKinsey & Company in Paris, Moscow and Brussels from 1998 to 2005.
Mr Helfgott serves as President of the Council of the Novo Nordisk
Haemophilia Foundation (NNHF).
Mr Helfgott is a French national, born July 1974.